Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1 2Phase 3 1

Status

Completed 5

Sponsor Class

INDUSTRY 5

Study Type

Interventional 5

Sponsor

Cancer Type

Plasma cell 5Other solid neoplasm 3Other hematologic neoplasm 3Lymphoid 3Thoracic 2Tumor-Agnostic 1Genitourinary 1Gastrointestinal 1Breast 1

Conditions

Multiple Myeloma 5Recurrence 1

Interventions

Dexamethasone 315Bortezomib 166Lenalidomide 132pomalidomide 113daratumumab 96carfilzomib 69Cyclophosphamide 44Calcium Dobesilate 41belantamab mafodotin 32elotuzumab 31fludarabine 27ixazomib 24isatuximab 21Melphalan 21venetoclax 18selinexor 17talquetamab 15Prednisone 15plerixafor 14Panobinostat 14Granulocyte Colony-Stimulating Factor 14Injections 12idecabtagene vicleucel 11Zoledronic Acid 11Thalidomide 11Azacitidine 11pembrolizumab 10tocilizumab 9nirogacestat 9liposomal doxorubicin 9

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
INDUSTRY × WW Domain-Containing Oxidoreductase × Plasma cell × Clear all
NCT02412878 2022-09-23

ARROW

Amgen

Phase 3 Completed
478 enrolled 17 charts
Plasma cell

Multiple Myeloma

NCT02335983 2020-11-06

Phase 1b Study of Weekly Carfilzomib in Combination With Lenalidomide and Dexamethasone in Subjects With Multiple Myeloma

Amgen

Phase 1 Completed
107 enrolled 25 charts
Plasma cell

Multiple Myeloma

NCT00511238 2017-08-31

Phase 2 Study of Carfilzomib in Relapsed and Refractory Multiple Myeloma

Amgen

Phase 2 Completed
312 enrolled 16 charts
Plasma cell

Multiple Myeloma, Recurrence

NCT01980589 2017-05-30

CHAMPION 2

Amgen

Phase 1 Completed
22 enrolled 11 charts
Plasma cell

Multiple Myeloma

NCT00530816 2017-05-02

Phase 2 Study of Carfilzomib in Relapsed Multiple Myeloma

Amgen

Phase 2 Completed
164 enrolled 16 charts
Plasma cell

Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡